We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

56 hedge funds and large institutions have $216M invested in Adaptimmune Therapeutics in 2017 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 3

14% more funds holding

Funds holding: 49 → 56 (+7)

1.98% more ownership

Funds ownership: 9.36% → 11.33% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less capital invested

Capital invested by funds: $219M → $216M (-$2.84M)

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

Holders
56
Holders Change
+7
Holders Change %
+14.29%
% of All Funds
1.4%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
12
Reduced
13
Closed
3
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
MCMC
Matrix Capital Management Company
New Hampshire
+$45.4M
2
Baillie Gifford & Co
Baillie Gifford & Co
United Kingdom
+$2.1M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.51M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$985K
5
EIM
Essex Investment Management
Massachusetts
+$791K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.33M
2
Millennium Management
Millennium Management
New York
-$2.47M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$295K
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$220K
5
Axa
Axa
France
-$170K
Name Holding Trade Value Shares
Change 		Change in
Stake
WMSA
26
Weiss Multi-Strategy Advisers
New York
$453K -$47K -9,000 -8%
BBA
27
Baker Bros. Advisors
New York
$449K – – –
PCM
28
Prelude Capital Management
New York
$441K +$411K +78,677 +403%
State Street
29
State Street
Massachusetts
$295K – – –
AA
30
ALPS Advisors
Colorado
$287K +$15.7K +2,996 +5%
CLOS
31
Compagnie Lombard Odier SCmA
Switzerland
$258K – – –
GCP
32
GSA Capital Partners
United Kingdom
$242K +$282K +53,866 New
VKH
33
Virtu KCG Holdings
New York
$226K +$136K +26,105 +108%
Creative Planning
34
Creative Planning
Kansas
$182K – – –
DADC
35
D.A. Davidson & Co
Montana
$161K -$6.93K -1,326 -4%
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$159K -$295K -56,371 -61%
OAM
37
Oxford Asset Management
United Kingdom
$156K +$182K +34,767 New
Geode Capital Management
38
Geode Capital Management
Massachusetts
$128K +$61.5K +11,764 +70%
ARTA
39
A.R.T. Advisors
New York
$108K -$50.5K -9,665 -29%
State of New Jersey Common Pension Fund D
40
State of New Jersey Common Pension Fund D
New Jersey
$108K – – –
RJFSA
41
Raymond James Financial Services Advisors
Florida
$91K -$7.98K -1,527 -7%
Citadel Advisors
42
Citadel Advisors
Florida
$89K +$103K +19,759 New
NSEDCP
43
NJ State Employees Deferred Compensation Plan
New Jersey
$71K – – –
GT
44
Glenmede Trust
Pennsylvania
$48K – – –
Goldman Sachs
45
Goldman Sachs
New York
$46K +$53.6K +10,251 New
Morgan Stanley
46
Morgan Stanley
New York
$42K +$3.65K +698 +8%
Wells Fargo
47
Wells Fargo
California
$32K -$2.61K -500 -7%
JP Morgan Chase
48
JP Morgan Chase
New York
$27K -$75.8K -14,500 -70%
TRCT
49
Tower Research Capital (TRC)
New York
$16K +$19.1K +3,663 New
UBS Group
50
UBS Group
Switzerland
$9K +$6.42K +1,228 +159%
1
2
3

ADAP Hedge Fund Activity: Q2 2017 in Review

56 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2017, worth a combined $216M — down 1.3% from $219M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new ADAP positions and 3 closed out — a net gain of 7 holders — while 12 added to existing stakes and 13 trimmed.

The largest buyer was Matrix Capital Management Company, opening a new position worth an estimated $45.4M. The largest seller was Fidelity Investments, cutting an estimated $5.33M.

  • 56 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2017, up from 49 in Q1 2017.
  • Funds reported $216M of Adaptimmune Therapeutics stock for Q2 2017, down 1.3% quarter-over-quarter.
  • 10 funds opened new Adaptimmune Therapeutics positions in Q2 2017 and 3 closed out, a net change of +7 holders.
  • The largest Adaptimmune Therapeutics buyer in Q2 2017 was Matrix Capital Management Company, an estimated $45.4M added.
  • The largest Adaptimmune Therapeutics seller in Q2 2017 was Fidelity Investments, an estimated $5.33M sold.

Based on aggregated 13F filings for Q2 2017.